Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Vtv Theraptcs Cl A (VTVT)
Vtv Theraptcs Cl A (VTVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 86,245
  • Shares Outstanding, K 104,577
  • Annual Sales, $ 2,020 K
  • Annual Income, $ -19,160 K
  • 60-Month Beta -1.20
  • Price/Sales 43.53
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade VTVT with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.25
  • Most Recent Earnings -0.06 on 05/11/23
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.04
  • Growth Rate Est. (year over year) -125.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7254 +13.69%
on 05/05/23
0.9900 -16.70%
on 06/01/23
+0.0347 (+4.39%)
since 05/02/23
3-Month
0.7000 +17.81%
on 04/13/23
0.9900 -16.70%
on 06/01/23
+0.0270 (+3.38%)
since 03/02/23
52-Week
0.6100 +35.20%
on 06/07/22
1.4000 -41.09%
on 08/15/22
+0.1063 (+14.80%)
since 06/02/22

Most Recent Stories

More News
CANTEX PHARMACEUTICALS OBTAINS EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM GEORGETOWN UNIVERSITY FOR AZELIRAGON AS A POTENTIAL TREATMENT OF CANCER-RELATED COGNITIVE DECLINE

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 0.8247 (-1.81%)
VTv Therapeutics: Q1 Earnings Snapshot

VTv Therapeutics: Q1 Earnings Snapshot

VTVT : 0.8247 (-1.81%)
Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 0.8247 (-1.81%)
Promising Upsides on these Biotech Penny Stocks

These three biotech stocks each have a consensus Buy rating. While they are down from historic highs, impressive upsides make them worth consideration.

VTVT : 0.8247 (-1.81%)
SABS : 0.9166 (+0.73%)
GMDA : 2.37 (+9.72%)
VTv Therapeutics: Q4 Earnings Snapshot

VTv Therapeutics: Q4 Earnings Snapshot

VTVT : 0.8247 (-1.81%)
Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 0.8247 (-1.81%)
Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

/PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...

VTVT : 0.8247 (-1.81%)
VTv Therapeutics (VTVT) Reports Q3 Loss, Lags Revenue Estimates

vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

VTVT : 0.8247 (-1.81%)
ANGN : 1.0000 (+2.04%)
Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of 23.64% and 4.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

EXAS : 83.84 (unch)
VTVT : 0.8247 (-1.81%)
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ACAD : 24.61 (+2.97%)
VTVT : 0.8247 (-1.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical...

See More

Key Turning Points

3rd Resistance Point 0.9005
2nd Resistance Point 0.8752
1st Resistance Point 0.8500
Last Price 0.8247
1st Support Level 0.7995
2nd Support Level 0.7742
3rd Support Level 0.7490

See More

52-Week High 1.4000
Fibonacci 61.8% 1.0982
Fibonacci 50% 1.0050
Fibonacci 38.2% 0.9118
Last Price 0.8247
52-Week Low 0.6100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar